Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPensionProperty, Plant & Equipment (Net)Retained EarningsShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abivax (ABVX) Assets (2021 - 2025)

Historic Assets for Abivax (ABVX) over the last 5 years, with Q3 2025 value amounting to $762.3 million.

  • Abivax's Assets changed N/A to $762.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $762.3 million, marking a year-over-year change of. This contributed to the annual value of $219.3 million for FY2024, which is 3801.22% down from last year.
  • Per Abivax's latest filing, its Assets stood at $762.3 million for Q3 2025.
  • Abivax's 5-year Assets high stood at $762.3 million for Q3 2025, and its period low was $77.1 million during Q4 2022.
  • Its 5-year average for Assets is $269.1 million, with a median of $197.5 million in 2024.
  • Its Assets has fluctuated over the past 5 years, first soared by 35657.56% in 2023, then tumbled by 5579.51% in 2025.
  • Quarter analysis of 5 years shows Abivax's Assets stood at $125.0 million in 2021, then tumbled by 38.32% to $77.1 million in 2022, then soared by 356.58% to $351.9 million in 2023, then plummeted by 37.68% to $219.3 million in 2024, then surged by 247.59% to $762.3 million in 2025.
  • Its Assets was $762.3 million in Q3 2025, compared to $135.4 million in Q2 2025 and $175.6 million in Q1 2025.